Library
4Cl-iBF
Potency of 4Cl-iBF is not precisely established but in vitro binding suggests it is weaker than fentanyl yet far more potent than morphine - DO NOT eyeball powder; use a calibrated 0.1 mg (100 ug) scale or volumetric solution. Numerous post-mortem and seized-sample reports confirm involvement in fatal overdoses; naloxone reverses toxicity but may require repeated dosing because of longer half-life than naloxone. Strong histamine release and chest-wall rigidity have been described with analogous compounds. Always employ test-dose strategy and never use alone - respiratory depression can appear abruptly during or immediately after peak. Fentanyl testing strips are unlikely to detect 4Cl-iBF reliably.
Also known as: P-chloro-isobutyrylfentanyl, Para-chloroisobutyrylfentanyl, P-Cl-iBF, 4-Chloroisobutyrfentanyl, 4-chloro-isobutylfentanyl
Classification
- Chemical: Anilidopiperidine
- Chemical: Opioid
- Psychoactive: Depressant
- Tag: Anilinopiperidine
- Tag: Fentanyl analogue
- Tag: Habit-Forming
- Tag: Research-Chemical
- Tag: Synthetic opioid
Effects
- Analgesia
- Sedation
- Anxiolysis
- Itching
- Miosis
- Nausea
- Euphoria
- Dizziness
- Anxiety Suppression
- Sadness
- Cognitive Euphoria
- Compulsive Redosing
- Dulled Perception
- Open Eye Visuals
- Sound Dampening
Routes of Administration
Insufflated
Dosage
- Threshold: 10-20 ug
- Light: 20-40 ug
- Common: 40-80 ug
- Strong: 80-150 ug
- Heavy: >150 µg
Duration
- Onset: 0.03-0.08 h
- Peak: 0.25-0.75 h
- Offset: 1-2 h
- After Effects: 2-6 h
- Total Duration: 1.5-3 h
Sublingual
Dosage
- Threshold: 15-30 ug
- Light: 30-60 ug
- Common: 60-120 ug
- Strong: 120-200 ug
- Heavy: >200 µg
Duration
- Onset: 0.08-0.25 h
- Peak: 0.25-0.75 h
- Offset: 1-2 h
- After Effects: 2-6 h
- Total Duration: 2-4 h
Intravenous
Dosage
- Threshold: 5-10 ug
- Light: 10-25 ug
- Common: 25-50 ug
- Strong: 50-100 ug
- Heavy: >100 µg
Duration
- Peak: 0.25-0.75 h
- Offset: 0.75-1.5 h
- After Effects: 1.5-6 h
- Onset: 0-0.02 h
- Total Duration: 1-2 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
Links
This static page is intended as a readable non-JS and prerender-friendly library export.
